Knight Therapeutics Inc
CIK: 0001756235
Associated companies
Transaction History
| SXTP | ▼ Sell | Other | 2,162 | $0 | 7/28/2023 | View on chart |
| SXTP | ▼ Sell | Other | 45,560 | $216K | 7/28/2023 | View on chart |
| SXTP | ▼ Sell | Other | 2,162 | $0 | 7/28/2023 | View on chart |
| SXTP | ▼ Sell | Other | 45,560 | $216K | 7/28/2023 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
SXTP to Release Babesiosis Interim Data and Appear on CNBC
60 Degrees Pharmaceuticals will share interim results from its hospitalized babesiosis study and host a key‑opinion‑leader webinar later this month. The company will also discuss the data on the RedChip Small Stocks, Big Money show broadcast on CNBC and Bloomberg TV. A separate presentation of tafenoquine trial analysis is scheduled for Oct. 6. These events raise the profile of the company's clinical program.
SXTP to Release Babesiosis Interim Data and Appear on CNBC. 60 Degrees Pharmaceuticals will share interim results from its hospitalized babesiosis study and host a key‑opinion‑leader webinar later this month. The company will also discuss the data on the RedChip Small Stocks, Big Money show broadcast on CNBC and Bloomberg TV. A separate presentation of tafenoquine trial analysis is scheduled for Oct. 6. These events raise the profile of the company's clinical program.